Treprostinil Treatment Study for Pulmonary Hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This study looks at how well the drug Treprostinil works in people with a specific type of pulmonary hypertension (high blood pressure in the lungs). It helps researchers understand real-world results and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with Group 1 pulmonary hypertension, also called PAH.
- You started treatment with Treprostinil through an injection under the skin or into a vein on or after January 1, 2024.
- You are not currently participating in another research study for your pulmonary hypertension.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if treprostinil can help people with pulmonary arterial hypertension (PAH) who are at intermediate risk. You may join if you have been diagnosed with certain types of PAH and meet specific heart and lung test results.
This study tests whether changing from the oral medicine selexipag to an inhaled treatment called treprostinil (LIQ861) can improve symptoms or be better tolerated in adults with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs. If you are currently taking selexipag but it isn't working well enough or causes side effects, this switch might be a good option for you.
This trial tests whether adding a new drug called tiprelestat to standard pulmonary arterial hypertension (PAH) treatments can help patients breathe better and feel stronger. You'd receive tiprelestat or placebo along with your current PAH medications.
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
This trial tests whether an inhaled medication called treprostinil can improve exercise ability in people with exercise-induced pulmonary hypertension. It aims to see if the drug helps with shortness of breath during activity.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.